Engineered immune cells take on tough blood cancers
NCT ID NCT06705530
First seen Feb 16, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This study tested a new treatment called anti-CD19 CAR-T cell therapy for adults with B-cell blood cancers that came back or didn't respond to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target and kill cancer cells. The study included 58 adults aged 18-70, who received chemotherapy before the CAR-T cells were given through an IV. Researchers monitored safety and how well the treatment controlled the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Medical Research Center for Hematology
Moscow, 125167, Russia
Conditions
Explore the condition pages connected to this study.